Articles tagged as

Drug Manufacturers - Major

  • Showing 1-100 of 116 items
  • 1
  • 2
  • >>
  1. Gilead Stock: Analyzing 5 Key Suppliers (GILD)

  2. (VRX) Who are Valeant's Main Competitors?

  3. Top 3 Companies Owned by Valeant (VRX)

  4. Singer Gets Better End of AGN-PFE Deal Implosion

  5. Is it too Late to Invest in Synergy Pharmaceuticals? (SGYP)

  6. Is there any Upside in Neurocine Biosciences, Inc? (NBIX)

  7. FPHAX: Overview of Fidelity Select Pharmaceuticals Fund

  8. The 5 Highest Paid Executives in the Healthcare Sector (AGN, PFE)

  9. Has Gilead Sciences Become a Value Stock? (GILD)

  10. 4 Reasons Behind Bill Ackman's Purchase of Zoetis Stock (ZTS, PFE)

  11. Is Big Pharma Under Pressure in 2016? (JNJ, GSK)

  12. Novo Nordisk: The Drug Firm You've Yet to Hear Of

  13. Gilead's 3 Most Profitable Lines of Business (GILD)

  14. Johnson & Johnson's Partnership with Nextera (JNJ)

  15. Analyzing Pfizer's Return on Equity (ROE) (PFE)

  16. The Cancer (and Other Drug) Shortage

  17. Celgene's 3 Key Financial Ratios (CELG)

  18. 3 Drugs That Could Bankrupt Medicare (GILD)

  19. Pfizer's 3 Key Financial Ratios (PFE)

  20. Johnson & Johnson's 3 Key Financial Ratios (JNJ)

  21. Analyzing Amgen's Debt Ratios in 2016 (AMGN)

  22. Top 5 Positions in Dodge & Cox's Portfolio (HPQ, SLB)

  23. Is Pfizer Stock Suitable for Your IRA or Roth IRA? (PFE)

  24. Amgen: An Activist Investment Analysis (AMGN)

  25. Analyzing Amgen's Price & Profitability Ratios in 2016 (AMGN)

  26. How Soon Will We Get a Zika Vaccine?

  27. Gilead's 3 Key Financial Ratios (GILD)

  28. How Medtronic Makes Money (MDT)

  29. Yo Shkreli: Kanye Doesn't Want Your $10M, Bromance

  30. Forest Laboratories: An Activist Investment Analysis

  31. Zika: Study Says This Device Could Protect You

  32. How Pharmaceutical Companies Price Their Drugs

  33. Jana Partners: An Activist Investor Analysis

  34. The Biggest Risks of Investing in Johnson & Johnson Stock (JNJ)

  35. The Biggest Risks of Investing in Celgene Stock (CELG)

  36. In Pain? Sanofi Has a Cure for That (SNY)

  37. Allergan: An Activist Investment Analysis (AGN,VRX)

  38. JNJ vs. PG: Which is the Better Bet Right Now?

  39. 2016's Most Promising Stocks (INTC, IBM)

  40. Novartis Stock: A Dividend Analysis (NVS)

  41. How Novartis Probably Has a Cure for What Ails You

  42. Are These the Top Biotech Stocks of 2016?

  43. How the New Allergan Plc Will Make Money

  44. Healthcare Stocks: Are These 2016's Best?

  45. Is Johnson & Johnson Stock Suitable for Your IRA or Roth IRA? (JNJ)

  46. The Top 5 Health Care ETFs for 2016 (XLV, VHT)

  47. The Top 5 Large-Cap Healthcare Stocks for 2016 (GILD, ANTM)

  48. PJP: PowerShares Dynamic Pharmaceuticals ETF

  49. The World's Top 10 Biotechnology Companies (JNJ, ROG.VX)

  50. CURE: Direxion Daily Healthcare Bull 3X ETF

  51. PPH: Market Vectors Pharmaceutical ETF

  52. Roche Stock: A Dividend Analysis

  53. 3 of America's Most Expensive Drugs and Who Profits From Them

  54. 4 Reasons Gilead Sciences Should be in Your Stock Portfolio (GILD)

  55. The Biggest Risks of Investing in Pfizer Stock (PFE)

  56. Johnson & Johnson Stock: A Dividend Analysis (JNJ)

  57. This Resilient Stock Should be on Your Watch List

  58. The 5 Best Dividend Stocks in the Healthcare Sector (GSK, ABBV)

  59. Top 5 Health Mutual Funds

  60. Should You Avoid Biotech Stocks Right Now? (LABD, IBB)

  61. 4 Trends Driving M&A in the Healthcare Industry in 2015

  62. Are Drug Price Controls Viable in the U.S.? (IPXL, ABBV)

  63. Healthcare M&A and Prescription Drug Prices

  64. Valeant Pharmaceuticals acquires Sprout Pharmaceuticals (VRX)

  65. Is the Ebola Epidemic Officially Over?

  66. Sarepta Therapeutics Made Investors Millionaires in 2 Years

  67. Celgene Vs. Gilead: Vetting for the Best Biopharma

  68. Make Room for Exelixis in Your Portfolio

  69. Drugmaker Extraordinaire: How Eli Lilly Grows

  70. Are Bears About to Burst the Biotech Bubble? (IBB, BIB)

  71. Pfizer CEO: The Story Behind Ian Read (PFE, AZN)

  72. 10 Developments By Gilead Sciences That Could Boost Profits (GILD)

  73. Are These 2015's 10 Best Generic Pharma Stocks?

  74. How to Profit from the Generic Drug Trend

  75. From Startup To Blue Chip: The Success Story Of Gilead Sciences Inc.

  76. Top 10 Pfizer Venture Investments (PFE)

  77. Is It Too Late To Invest In Gilead Sciences? (GILD)

  78. How Does Biogen Make its Money?

  79. Small-Cap Biotech Stocks to Watch

  80. Are These the Top 3 Value Stocks of 2015?

  81. 3 Top Pharma Stocks that Pay Regular Dividends (GSK, AZN)

  82. How to Analyze Pharma Stock Fundamentals

  83. How Bristol-Myers Squibb Makes the World Healthier

  84. How is a Spinoff Worth $100 Billion? See AbbVie

  85. Why These Could Be 2015's 10 Best Biotech Stocks

  86. Why These Could Be 2015's 10-Best Pharma Stocks (ABBV, ALXN)

  87. Why These ETFs are the Best Way to Trade Pfizer

  88. Could Amgen's Next Drug Be Worth $100 Billion?

  89. Has The Time Come To Sell Vertex Pharmaceuticals?

  90. Why Celgene Won't Pay A Dividend Anytime Soon

  91. Could This Drug Make Isis Pharmaceuticals Soar?

  92. What Biotech Stock To Buy When The Market Tumbles?

  93. Did Orexigen Make A Big Mistake?

  94. Are These Biogen Idec's Next Blockbusters?

  95. Why Does Wall Street Hate MannKind?

  96. Is Exelixis Under-the-Radar Growth?

  97. Is Arena Pharmaceuticals In Trouble? (ARNA)

  98. What’s The Drug That Will Finally Fight Obesity?

  99. Should You Invest In Oraganovo Holdings?

  100. What Is Amgen’s New Target?

  • Showing 1-100 of 116 items
  • 1
  • 2
  • >>
Trading Center